KR20190057066A - 세니크리비록 메실레이트의 고체 형태 및 세니크리비록 메실레이트의 고체 형태의 제조 방법 - Google Patents

세니크리비록 메실레이트의 고체 형태 및 세니크리비록 메실레이트의 고체 형태의 제조 방법 Download PDF

Info

Publication number
KR20190057066A
KR20190057066A KR1020197008786A KR20197008786A KR20190057066A KR 20190057066 A KR20190057066 A KR 20190057066A KR 1020197008786 A KR1020197008786 A KR 1020197008786A KR 20197008786 A KR20197008786 A KR 20197008786A KR 20190057066 A KR20190057066 A KR 20190057066A
Authority
KR
South Korea
Prior art keywords
crystalline form
compound
msoh
acetonitrile
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197008786A
Other languages
English (en)
Korean (ko)
Inventor
파시트 피아시봉사
마틴 이안 쿠퍼
엠마 케이 샤프
Original Assignee
토비라 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토비라 쎄라퓨틱스, 인크. filed Critical 토비라 쎄라퓨틱스, 인크.
Publication of KR20190057066A publication Critical patent/KR20190057066A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197008786A 2016-08-31 2017-08-30 세니크리비록 메실레이트의 고체 형태 및 세니크리비록 메실레이트의 고체 형태의 제조 방법 Withdrawn KR20190057066A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
US62/382,153 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
KR20190057066A true KR20190057066A (ko) 2019-05-27

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008786A Withdrawn KR20190057066A (ko) 2016-08-31 2017-08-30 세니크리비록 메실레이트의 고체 형태 및 세니크리비록 메실레이트의 고체 형태의 제조 방법

Country Status (13)

Country Link
US (1) US10301287B2 (enExample)
EP (1) EP3506896A4 (enExample)
JP (2) JP2019526628A (enExample)
KR (1) KR20190057066A (enExample)
CN (1) CN110167550A (enExample)
AU (1) AU2017321594A1 (enExample)
BR (1) BR112019003987A2 (enExample)
CA (1) CA3034606A1 (enExample)
MX (1) MX2019002057A (enExample)
RU (1) RU2019109019A (enExample)
SG (1) SG11201901438VA (enExample)
TW (1) TW201823235A (enExample)
WO (1) WO2018045043A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11613670B2 (en) 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245589A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245534A1 (en) * 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
KR20210053921A (ko) * 2018-08-31 2021-05-12 에보니크 오퍼레이션즈 게엠베하 중합체 분말을 제조하는 방법
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
EP4159730A4 (en) 2020-05-22 2024-05-01 Medshine Discovery Inc. PYRIDINE DERIVATIVE AND APPLICATION THEREOF
US20240124690A1 (en) * 2021-02-22 2024-04-18 Asahi Kasei Kabushiki Kaisha Composition Containing Cellulose Nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
EP1104416A2 (en) 1998-08-20 2001-06-06 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
CA2384145A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
EP1728504B1 (en) 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2818308A1 (en) 2010-11-18 2012-05-24 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
CA2941411A1 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
WO2015187663A1 (en) * 2014-06-02 2015-12-10 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
SG11201704837VA (en) 2014-12-23 2017-07-28 Tobira Therapeutics Inc Process of making cenicriviroc and related analogs

Also Published As

Publication number Publication date
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21
RU2019109019A3 (enExample) 2021-08-23
WO2018045043A1 (en) 2018-03-08
RU2019109019A (ru) 2020-10-01
US20180057481A1 (en) 2018-03-01
SG11201901438VA (en) 2019-03-28
TW201823235A (zh) 2018-07-01
CN110167550A (zh) 2019-08-23
AU2017321594A1 (en) 2019-04-18
US10301287B2 (en) 2019-05-28
BR112019003987A2 (pt) 2019-05-28
EP3506896A1 (en) 2019-07-10
MX2019002057A (es) 2019-11-18
EP3506896A4 (en) 2020-08-26
CA3034606A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US10301287B2 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
KR102557321B1 (ko) Rad1901-2hcl의 다형 형태
JP2022088504A (ja) Ｌ－オルニチンフェニルアセテートおよびその製造方法
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
EP3344607B1 (en) Solid state forms of selexipag
RU2704795C2 (ru) Кристаллическая форма бисульфата ингибитора jak и способ ее получения
JP6193762B2 (ja) １−｛（２Ｓ）−２−アミノ−４−［２，４−ビス（トリフルオロメチル）−５，８−ジヒドロピリド［３，４−ｄ］ピリミジン−７（６Ｈ）−イ
CN112423844A (zh) Rad1901-2hcl的多晶型形式
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
KR20200138283A (ko) 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
KR20240019116A (ko) (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
JP2005298424A (ja) エパルレスタット結晶の製造方法
WO2018022704A1 (en) Crystalline form vi of selexipag
TW202545917A (zh) Ｎ－［（１ｓ，２ｅ）－１－環丙基－３－（甲磺醯基）丙－２－烯－１－基］－２－（１，１－二氟乙基）－４－苯氧基嘧啶－５－甲醯胺的新固體形式
TWI724651B (zh) 貝前列素-314d單水合物晶體及其製備方法
EP3272734A1 (en) Ahu377 crystal form, preparation method and use thereof
US11434204B2 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
CN114716410A (zh) 喹啉衍生物的结晶
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
RU2792728C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ 3-[5-АМИНО-4-(3-ЦИАНОБЕНЗОИЛ)ПИРАЗОЛ-1-ил]-N-ЦИКЛОПРОПИЛ-4-МЕТИЛБЕНЗАМИДА
HK40103083A (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
HK40076561A (en) Crystals of quinoline derivatives
HK40001929B (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
HK40001929A (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
HK40065390B (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200828

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220526

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220609

WITB Written withdrawal of application